Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
VINC Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 13, 2025
Report Source: 2025 1st Quarter Report
Vincerx Pharma Inc. Stock Analysis VINC
United States Health Care Nano Cap Report: Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
Read More Vincerx Pharma Inc (VINC) Chart
Key Statistics of Vincerx Pharma Inc (VINC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.13Volume
1282.00P/E Ratio (TTM)
-52 Week Range
Market Cap
70.00KAvg. Volume
135.50KDividend Yield
-Financial Metrics & Statements of Vincerx Pharma Inc (VINC)
FAQ's for Vincerx Pharma Inc (VINC)
- According to Musaffa’s Shariah screening methodology, Vincerx Pharma Inc (VINC) is currently classified as NOT HALAL as of June 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Vincerx Pharma Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Vincerx Pharma Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Vincerx Pharma Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Vincerx Pharma Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Vincerx Pharma Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.